Mason Carrico
Stock Analyst at Stephens & Co.
(0.92)
# 3,563
Out of 4,829 analysts
76
Total ratings
22.22%
Success rate
-12.74%
Average return
Main Sectors:
Stocks Rated by Mason Carrico
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CDNA CareDx | Reiterates: Overweight | $40 | $15.36 | +160.42% | 10 | May 5, 2025 | |
| GKOS Glaukos | Maintains: Overweight | $140 → $115 | $89.96 | +27.83% | 1 | May 2, 2025 | |
| VCYT Veracyte | Reiterates: Overweight | $45 | $29.71 | +51.46% | 7 | Mar 26, 2025 | |
| OCX OncoCyte | Reiterates: Equal-Weight | $4 | $2.87 | +39.37% | 5 | Mar 26, 2025 | |
| GH Guardant Health | Reiterates: Overweight | $55 | $41.72 | +31.83% | 5 | Mar 26, 2025 | |
| AKYA Akoya Biosciences | Downgrades: Equal-Weight | $3.5 → $1.8 | $1.10 | +63.64% | 6 | Mar 25, 2025 | |
| CTKB Cytek Biosciences | Reiterates: Overweight | $6 | $2.93 | +105.13% | 2 | Mar 19, 2025 | |
| STAA STAAR Surgical Company | Reiterates: Equal-Weight | $17 | $19.42 | -12.46% | 2 | Mar 18, 2025 | |
| ILMN Illumina | Reiterates: Overweight | $156 | $75.76 | +105.91% | 7 | Mar 11, 2025 | |
| ESTA Establishment Labs Holdings | Reiterates: Overweight | $52 | $33.92 | +53.30% | 2 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $2.5 | $1.12 | +123.21% | 4 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $84 | $56.75 | +48.02% | 3 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $20 | $3.89 | +414.14% | 4 | Jan 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $41.72 | +55.80% | 1 | Jan 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $41 | $16.81 | +143.90% | 7 | Jan 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $30 | $8.77 | +242.08% | 5 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $125 | $151.95 | -17.74% | 4 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $19 | $8.05 | +136.02% | 1 | Jul 30, 2024 |
CareDx
May 5, 2025
Reiterates: Overweight
Price Target: $40
Current: $15.36
Upside: +160.42%
Glaukos
May 2, 2025
Maintains: Overweight
Price Target: $140 → $115
Current: $89.96
Upside: +27.83%
Veracyte
Mar 26, 2025
Reiterates: Overweight
Price Target: $45
Current: $29.71
Upside: +51.46%
OncoCyte
Mar 26, 2025
Reiterates: Equal-Weight
Price Target: $4
Current: $2.87
Upside: +39.37%
Guardant Health
Mar 26, 2025
Reiterates: Overweight
Price Target: $55
Current: $41.72
Upside: +31.83%
Akoya Biosciences
Mar 25, 2025
Downgrades: Equal-Weight
Price Target: $3.5 → $1.8
Current: $1.10
Upside: +63.64%
Cytek Biosciences
Mar 19, 2025
Reiterates: Overweight
Price Target: $6
Current: $2.93
Upside: +105.13%
STAAR Surgical Company
Mar 18, 2025
Reiterates: Equal-Weight
Price Target: $17
Current: $19.42
Upside: -12.46%
Illumina
Mar 11, 2025
Reiterates: Overweight
Price Target: $156
Current: $75.76
Upside: +105.91%
Establishment Labs Holdings
Mar 6, 2025
Reiterates: Overweight
Price Target: $52
Current: $33.92
Upside: +53.30%
Feb 18, 2025
Reiterates: Overweight
Price Target: $2.5
Current: $1.12
Upside: +123.21%
Feb 6, 2025
Reiterates: Overweight
Price Target: $84
Current: $56.75
Upside: +48.02%
Jan 16, 2025
Reiterates: Equal-Weight
Price Target: $20
Current: $3.89
Upside: +414.14%
Jan 15, 2025
Reiterates: Overweight
Price Target: $65
Current: $41.72
Upside: +55.80%
Jan 2, 2025
Reiterates: Overweight
Price Target: $41
Current: $16.81
Upside: +143.90%
Oct 10, 2024
Reiterates: Overweight
Price Target: $30
Current: $8.77
Upside: +242.08%
Aug 9, 2024
Reiterates: Overweight
Price Target: $125
Current: $151.95
Upside: -17.74%
Jul 30, 2024
Reiterates: Overweight
Price Target: $19
Current: $8.05
Upside: +136.02%